论文部分内容阅读
溶瘤病毒因具有选择性杀伤肿瘤细胞的特性,已成为目前较有前景的肿瘤治疗类药物。溶瘤病毒疗法的安全性和有效性在临床中已得到证实,但由于恶性肿瘤高度的异质性和复杂性使得溶瘤病毒单药治疗肿瘤的效果受限,因此溶瘤病毒联合其他肿瘤治疗药物一起协同治疗肿瘤将是未来肿瘤治疗的重要发展方向之一,有望为肿瘤的治疗带来新的突破。新近研究表明,不同的小分子抑制剂可通过多种机制控制肿瘤生长,其在体外协同溶瘤病毒能达到更优的肿瘤治疗效果。本文就目前溶瘤病毒联合小分子抑制剂治疗肿瘤的研究进展进行综述。
Oncolytic viruses have become the currently more promising tumor therapeutics because of their selective killing of tumor cells. The safety and efficacy of oncolytic therapies have been clinically proven, but oncolytic viruses, in combination with other oncology treatments, have been limited due to the limited effectiveness of oncolytic monotherapy in oncology due to the high degree of heterogeneity and complexity of the malignancies Collaborative treatment of drugs with drugs will be one of the important development directions of future cancer treatment, which is expected to bring new breakthroughs in the treatment of tumors. Recent studies have shown that different small molecule inhibitors can control tumor growth through a variety of mechanisms, and in vitro synergism with oncolytic virus can achieve better tumor therapeutic effect. This review summarizes the current progress in the oncolytic virus combined with small molecule inhibitors in the treatment of tumors.